Company profile · Kliniek / specialistische praktijk
Corvidane
- Pharmaceuticals
- Kliniek / specialistische praktijk
- Employees
- 2–10
- Founded
- 2014
- Country
- Netherlands
About Corvidane
Corvidane is developing Corvida™ to treat TWO formidable diseases.
Corvidane uses a novel approach to treat metabolic and inflammatory diseases.
Corvida(TM) for Atherosclerosis - In development to be a Best-in-Class, orally administered adjunct to lipid regulating therapies (Statins/PCSK9) that targets atherosclerotic plaques, the major factor in Heart Attacks and Stroke.
Corvida(TM) for MASH - In development to be a Best-in-Class, orally administered drug to treat MASH, which is the leading cause of liver transplants in the United States.
Address
Headquarters
Stationsplein 45Netherlands
Team by function
Based on 2 public job profiles as of 3 September 2026.
- Founder / Owner2
Similar companies
Companies with a similar profile.
Adcytherix
Biotechnology · Marseille
11–50 employeesView profile
Synaffix
Biotechnology
51–200 employeesView profile
Mirabilis Therapeutics BV
Biotechnology · Maastricht
2–10 employeesView profile
DiaphOne Therapeutics
Biotechnology · Amsterdam
2–10 employeesView profile
Ardent Biopharma
Biotechnology · Leiden
2–10 employeesView profile
Corporis Medical
Medical Devices · Maastricht
11–50 employeesView profile